{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:45:49Z","timestamp":1789865149824,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.yebeh.2019.106541","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T18:08:14Z","timestamp":1572890894000},"page":"106541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"PA","title":["Treatment with brivaracetam in children \u2013 The experience of a pediatric epilepsy center"],"prefix":"10.1016","volume":"101","author":[{"given":"Andreea","family":"Nissenkorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Tzadok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Bar-Yosef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruria","family":"Ben-Zeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.106541_bb0005","series-title":"Jasper's basic mechanisms of the epilepsies","article-title":"Targeting SV2A for discovery of antiepileptic drugs","author":"Kaminski","year":"2012"},{"key":"10.1016\/j.yebeh.2019.106541_bb0010","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.yebeh.2019.106541_bb0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/NDT.S2937","article-title":"Levetiracetam in the treatment of epilepsy","volume":"4","author":"Abou-Khalil","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2019.106541_bb0020","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617742081","article-title":"Brivaracetam: a novel antiepileptic drug for focal-onset seizures","volume":"11","author":"Stephen","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2019.106541_bb0025","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/14656566.2017.1359260","article-title":"Evaluation of brivaracetam: a new drug to treat epilepsy","volume":"18","author":"Milovanovic","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2019.106541_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2018.02.005","article-title":"Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: two double-blind, randomized, multicenter, historical control, phase III studies","volume":"141","author":"Arnold","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.106541_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yebeh.2017.12.024","article-title":"Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled phase III randomized, double-blind trials: a post-hoc analysis","volume":"80","author":"Benbadis","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106541_bb0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eplepsyres.2016.08.018","article-title":"Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase III studies","volume":"127","author":"Brodie","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.106541_bb0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/epi.12391","article-title":"Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial","volume":"55","author":"Kwan","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106541_bb0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eplepsyres.2016.09.003","article-title":"Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three phase III studies","volume":"127","author":"Moseley","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.106541_bb0055","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13059","article-title":"BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice","volume":"139","author":"Villanueva","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2019.106541_bb0060","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106541_bb0065","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fneur.2018.00569","article-title":"Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany","volume":"9","author":"Willems","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2019.106541_bb0070","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/epi.14476","article-title":"Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus","volume":"59","author":"Strzelczyk","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106541_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.yebeh.2018.10.018","article-title":"Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents","volume":"89","author":"Schubert-Bast","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106541_bb0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fneur.2018.00038","article-title":"Brivaracetam in the treatment of patients with epilepsy-first clinical experiences","volume":"9","author":"Zahnert","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2019.106541_bb0085","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1684\/epd.2017.0939","article-title":"Exceptional response to brivaracetam in a patient with refractory idiopathic generalized epilepsy and absence seizures","volume":"20","author":"Grande-Martin","year":"2018","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2019.106541_bb0090","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40262-017-0597-2","article-title":"Extrapolation of a brivaracetam exposure-response model from adults to children with focal seizures","volume":"57","author":"Schoemaker","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2019.106541_bb0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019307735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019307735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:31:02Z","timestamp":1761503462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019307735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":19,"alternative-id":["S1525505019307735"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106541","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with brivaracetam in children \u2013 The experience of a pediatric epilepsy center","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106541"}}